SAT-122 / Satya Pharma - LARVOL DELTA

Small molecule disruptor of RAD51:BRCA2 interaction reduces nuclear RAD51 foci and is efficacious in ovarian cancer pre-clinical model (EORTC-NCI-AACR 2024) - "IND enabling studies and translation studies are currently ongoing for testing SAT-122 in PARP resistant or chemotherapy resistant ovarian cancer."

Preclinical • Oncology • Ovarian Cancer • Solid Tumor • BRCA2 • HRD • RAD51

SAT-122: A potential first-in-class, potent, small-molecule disruptor of RAD51-BRCA2, attenuates RAD51 foci formation and tumor progression in preclinical models (ESMO 2023) - "Conclusions SAT-122 is a novel and potent disruptor of RAD51:BRCA2 with potential to be used in the DDR context, in solid tumors. IND-enabling studies are ongoing with clinical trials planned in H1 2024."

Preclinical • Oncology • Solid Tumor • BRCA2 • HRD • PARP1 • RAD51